GSK expands vaccine collaboration in China with Zhifei

UK pharma major GSK (LSE: GSK) has into an agreement with Chongqing Zhifei Biological Products (Zhifei) to revize the terms on which Zhifei will commercialize GSK’s shingles vaccine, Shingrix,in mainland China.

The revised agreement extends the original three-year period (2024-2026) during which Zhifei has exclusive rights to import, distribute and co-promote the vaccine in mainland China for an additional eight years through to 2034, with revised expected volumes. Under the revised agreement, Zhifei also agrees to engage exclusively with GSK to explore a potential collaboration, with an initial term of 10 years, on the commercialization of a respiratory syncytial virus (RSV) vaccine in mainland China, subject to regulatory approval of the vaccine.

Luke Miels, chief commercial officer, GSK, said: “This revised agreement with Zhifei puts our collaboration on a sustainable footing, managing challenges in the macro environment in the near-term, and helping us to reach even more Chinese people with our innovative adult vaccines over the long-term.”